The World Health Organization's ATC classification organizes medical drugs based on therapeutic properties, chemical composition, and anatomy. It helps make essential medicines readily available globally and is widely used in the pharmaceutical industry.
| Level | Code | Title | |
|---|---|---|---|
| 1 | N | Nervous system | |
| 2 | N07 | Other nervous system drugs | |
| 3 | N07A | Parasympathomimetics | |
| 4 | N07AA | Anticholinesterases |
| Code | Title | |
|---|---|---|
| N07AA01 | Neostigmine | |
| N07AA02 | Pyridostigmine | |
| N07AA03 | Distigmine | |
| N07AA30 | Ambenonium | |
| N07AA51 | Neostigmine, combinations |
| Active Ingredient | Description | |
|---|---|---|
| Ambenonium |
Ambenonium (as ambenonium dichloride) is a cholinesterase inhibitor used in the management of myasthenia gravis. Ambenonium exerts its actions against myasthenia gravis by competitive reversible inhibition of acetylcholinesterase, the enzyme responsible for the hydrolysis of acetylcholine. |
|
| Distigmine |
|
|
| Neostigmine |
Neostigmine inhibits cholinesterase activity and prolongs and intensifies the muscarinic and nicotinic effects of acetylcholine. The anticholinesterase actions of neostigmine are reversible. It is used mainly for its action on skeletal muscle and less frequently to increase the activity of smooth muscle. |
|
| Pyridostigmine |
Pyridostigmine is an antagonist to cholinesterase, the enzyme which normally destroys acetylcholine. The action of pyridostigmine can briefly be described, therefore, as the potentiation of naturally occurring acetylcholine. |
| Title | Information Source | Document Type | |
|---|---|---|---|
| MESTINON Tablet | Medicines & Healthcare Products Regulatory Agency (GB) | MPI, EU: SmPC | |
| UBRETID Tablet | Medicines & Healthcare Products Regulatory Agency (GB) | MPI, EU: SmPC |
